Eleven Biotherapeutics shares trade up after IPO


Shares of Eleven Biotherapeutics Inc. advanced 8.5 percent Thursday on their opening day of trading on the Nasdaq Stock Market after the Cambridge-based developer of protein drugs to treat eye diseases raised about $50 million in an initial public offering.

Eleven, a biotechnology company started and bankrolled by the venture capital firms Third Rock Ventures in Boston and Flagship Ventures in Cambridge, sold 5 million shares at $10 each — below its estimated price range of $13 to $15 a share. The share price traded up 85 cents, closing at $10.85.

The IPO was the third so far this year by a biotech in the state. Genocea Biosciences Inc., another Cambridge company, went public Wednesday, losing 8.3 percent in its first day of trading. And in the year’s first new Massachusetts biotech offering, Dicerna Pharmaceuticals Inc. of Watertown surged nearly 207 percent last week in its market debut.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of